|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 96 No. 2 (July 15), 2000:
pp. 768-770
BRIEF REPORT
Clinical relevance of intracellular vascular endothelial growth
factor levels in B-cell chronic lymphocytic leukemia
Alvaro Aguayo,
Susan O'Brien,
Michael Keating,
Taghi Manshouri,
Cristi Gidel,
Bart Barlogie,
Miloslav Beran,
Charles Koller,
Hagop Kantarjian, and
Maher Albitar
From the Departments of Leukemia and Hematopathology, University of
Texas MD Anderson Cancer Center, Houston, TX, and the
Myeloma and Transplantation Research Center, University of Arkansas for
Medical Sciences, Little Rock, AR.
Strong evidence exists for an association between high vascular
endothelial growth factor (VEGF) levels and poor prognoses in patients
with solid tumors and acute leukemia. Using Western blot analysis and
solid-phase radioimmunoassay, we measured cellular VEGF levels in
B-cell chronic lymphocytic leukemia (CLL) samples from 225 patients and
correlated these levels with disease characteristics and prognoses. The
median VEGF level in CLL samples was 7.26 times the median level
detected in normal peripheral blood mononuclear cells. Patients with
lower levels of VEGF protein showed a trend toward shorter survival
(P = .07). However, in a subgroup of CLL patients with good
prognoses or early-stage disease (Rai stages 0-II, Binet stages A,B;
 2-M  2.8 mg/dL), lower levels of VEGF were associated with
shorter survival times. For the entire group of patients, no
correlation was found between VEGF levels and 2-M levels or Rai and
Binet stage. Most samples from patients with CLL expressed the 43-kd
VEGF isoform in addition to the commonly expressed 45-kd isoform.
It remains to be seen whether the expression of the 43-kd isoform
is responsible for this reversed correlation with outcome.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Letter in Blood Online:
-
Dalteparin-induced alopecia in hemodialysis patients: reversal by regional citrate anticoagulation
- Robert Apsner, Walter H. Hörl, and Gere Sunder-Plassmann
Blood 2001 97: 2914-2915.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
P. E. M. Patten, A. G. S. Buggins, J. Richards, A. Wotherspoon, J. Salisbury, G. J. Mufti, T. J. Hamblin, and S. Devereux
CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment
Blood,
May 15, 2008;
111(10):
5173 - 5181.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. A. Avramis, E. H. Panosyan, F. Dorey, J. S. Holcenberg, and V. I. Avramis
Correlation between High Vascular Endothelial Growth Factor-A Serum Levels and Treatment Outcome in Patients with Standard-Risk Acute Lymphoblastic Leukemia: A Report from Children's Oncology Group Study CCG-1962
Clin. Cancer Res.,
December 1, 2006;
12(23):
6978 - 6984.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Battle, J. Arbiser, and D. A. Frank
The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells
Blood,
July 15, 2005;
106(2):
690 - 697.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. C. Hildebrandt, K. M. Olkiewicz, S. Choi, L. A. Corrion, S. G. Clouthier, C. Liu, J. S. Serody, and K. R. Cooke
Donor T-cell production of RANTES significantly contributes to the development of idiopathic pneumonia syndrome after allogeneic stem cell transplantation
Blood,
March 15, 2005;
105(6):
2249 - 2257.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Legros, C. Bourcier, A. Jacquel, F.-X. Mahon, J.-P. Cassuto, P. Auberger, and G. Pages
Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia
Blood,
July 15, 2004;
104(2):
495 - 501.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Decker, S. Hipp, I. Ringshausen, C. Bogner, M. Oelsner, F. Schneller, and C. Peschel
Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin
Blood,
January 1, 2003;
101(1):
278 - 285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Molica, A. Vacca, D. Ribatti, A. Cuneo, F. Cavazzini, D. Levato, G. Vitelli, L. Tucci, A. M. Roccaro, and F. Dammacco
Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia
Blood,
October 16, 2002;
100(9):
3344 - 3351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Albitar, T. Manshouri, Y. Shen, D. Liu, M. Beran, H. M. Kantarjian, A. Rogers, I. Jilani, C. W. Lin, S. Pierce, et al.
Myelodysplastic syndrome is not merely "preleukemia"
Blood,
July 18, 2002;
100(3):
791 - 798.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Verstovsek, H. Kantarjian, T. Manshouri, J. Cortes, F. J. Giles, A. Rogers, and M. Albitar
Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia
Blood,
March 15, 2002;
99(6):
2265 - 2267.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. E. Kay, T. J. Hamblin, D. F. Jelinek, G. W. Dewald, J. C. Byrd, S. Farag, M. Lucas, and T. Lin
Chronic Lymphocytic Leukemia
Hematology,
January 1, 2002;
2002(1):
193 - 213.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
F. J. Giles
The Vascular Endothelial Growth Factor (VEGF) Signaling Pathway: A Therapeutic Target in Patients with Hematologic Malignancies
Oncologist,
October 1, 2001;
6(2008):
32 - 39.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Peterson, A. R. Kini, and N. Kay
Angiogenesis is increased in B-cell chronic lymphocytic leukemia
Blood,
April 15, 2001;
97(8):
2529 - 2530.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Aguayo, H. Kantarjian, T. Manshouri, C. Gidel, E. Estey, D. Thomas, C. Koller, Z. Estrov, S. O'Brien, M. Keating, et al.
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
Blood,
September 15, 2000;
96(6):
2240 - 2245.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
